{"id":11401,"date":"2024-11-05T14:28:31","date_gmt":"2024-11-05T06:28:31","guid":{"rendered":"https:\/\/flcube.com\/?p=11401"},"modified":"2024-11-05T14:28:34","modified_gmt":"2024-11-05T06:28:34","slug":"novo-nordisk-secures-global-licensing-agreement-with-ascendis-pharma-for-transcon-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11401","title":{"rendered":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology"},"content":{"rendered":"\n

Denmark-based healthcare giant Novo Nordisk (NYSE: NVO<\/a>; CPH: NOVO-B<\/a>) has entered into a licensing agreement with compatriot firm Ascendis Pharma A\/S (NASDAQ: ASND<\/a>), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis\u2019 TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary products in metabolic diseases, including obesity and type 2 diabetes, as well as an exclusive license for cardiovascular diseases on a product-by-product basis.<\/p>\n\n\n\n

Lead Program and Financial Terms of the Agreement<\/strong>
The flagship program under this agreement is a once-monthly GLP-1 receptor agonist product candidate, which will initially focus on obesity and type 2 diabetes. Novo Nordisk is also granted exclusive rights to expand any metabolic disease products into other therapeutic areas. In return, Novo Nordisk will pay Ascendis up to USD 285 million in upfront, development, and regulatory milestone payments for the lead program, along with sales-based milestone payments and tiered royalties on global net sales. For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to USD 77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.<\/p>\n\n\n\n

Development and Commercialization Responsibilities<\/strong>
Ascendis will handle the early development of TransCon product candidates under the collaboration, while Novo Nordisk will cover the associated early development costs and take on responsibilities for clinical development, regulatory, commercial manufacturing, and commercialization.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":11402,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[392,1250,39,1195,148,860,86],"class_list":["post-11401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascendis-pharma","tag-cph-novo-b","tag-diabetes","tag-nasdaq-asnd","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"\nNovo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A\/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis\u2019 TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary products in metabolic diseases, including obesity and type 2 diabetes, as well as an exclusive license for cardiovascular diseases on a product-by-product basis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11401\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11401\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T06:28:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T06:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1653\" \/>\n\t<meta property=\"og:image:height\" content=\"758\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology\",\"datePublished\":\"2024-11-05T06:28:31+00:00\",\"dateModified\":\"2024-11-05T06:28:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401\"},\"wordCount\":247,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg\",\"keywords\":[\"Ascendis Pharma\",\"CPH: NOVO-B\",\"Diabetes\",\"NASDAQ: ASND\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11401#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11401\",\"name\":\"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg\",\"datePublished\":\"2024-11-05T06:28:31+00:00\",\"dateModified\":\"2024-11-05T06:28:34+00:00\",\"description\":\"Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A\\\/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis\u2019 TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary products in metabolic diseases, including obesity and type 2 diabetes, as well as an exclusive license for cardiovascular diseases on a product-by-product basis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11401\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg\",\"width\":1653,\"height\":758,\"caption\":\"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11401#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology - Insight, China's Pharmaceutical Industry","description":"Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A\/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis\u2019 TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary products in metabolic diseases, including obesity and type 2 diabetes, as well as an exclusive license for cardiovascular diseases on a product-by-product basis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11401","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11401","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-05T06:28:31+00:00","article_modified_time":"2024-11-05T06:28:34+00:00","og_image":[{"width":1653,"height":758,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11401#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11401"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology","datePublished":"2024-11-05T06:28:31+00:00","dateModified":"2024-11-05T06:28:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11401"},"wordCount":247,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=11401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","keywords":["Ascendis Pharma","CPH: NOVO-B","Diabetes","NASDAQ: ASND","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11401#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11401","url":"https:\/\/flcube.com\/?p=11401","name":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=11401#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=11401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","datePublished":"2024-11-05T06:28:31+00:00","dateModified":"2024-11-05T06:28:34+00:00","description":"Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A\/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis\u2019 TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary products in metabolic diseases, including obesity and type 2 diabetes, as well as an exclusive license for cardiovascular diseases on a product-by-product basis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11401#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11401"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=11401#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","width":1653,"height":758,"caption":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11401#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/faec28fc9ee43082ddfd2afaa6c7c31c.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11401"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11401\/revisions"}],"predecessor-version":[{"id":11403,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11401\/revisions\/11403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/11402"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}